AR075411A1 - Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa. - Google Patents

Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa.

Info

Publication number
AR075411A1
AR075411A1 ARP100100400A ARP100100400A AR075411A1 AR 075411 A1 AR075411 A1 AR 075411A1 AR P100100400 A ARP100100400 A AR P100100400A AR P100100400 A ARP100100400 A AR P100100400A AR 075411 A1 AR075411 A1 AR 075411A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
hydrogen
heteroaryl
aryl
Prior art date
Application number
ARP100100400A
Other languages
English (en)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David Middlemiss
Original Assignee
Fovea Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals Sa filed Critical Fovea Pharmaceuticals Sa
Publication of AR075411A1 publication Critical patent/AR075411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En particular se refieren al tratamiento o la mejora de un trastorno mediado por la cinasa, el cual incluye enfermedades cardiovasculares, diabetes, trastornos asociados con la diabetes, enfermedades inflamatorias, trastornos inmunologicos, cáncer y enfermedades de la vista tales como retinopatías o degeneracion macular u otras enfermedades vítreo retinales y similares. Reivindicacion 1: Los compuestos que tienen la estructura (1) como así también la sal, el hidrato o el solvato farmacéuticamente aceptable de los mismos en la cual A1 y A2 es N o C, con la condicion de que uno entre A1 o A2 sea N y uno entre A1 o A2 sea carbono, R1 y R2 son hidrogeno, arilo, heteroarilo, alquilo C1-4, -CN, -halogeno, -CF3, -OR4, R3 es hidrogeno, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alquilo C1-4, -CN, -CF3, -OR4, -OCOR4, -COR4, -NR4R5, -NR4COR5, -NR4COOR5, -(alquilo C1-4)OR4, -(alquilo C1-4)COR4, -(alquilo C1-4)NR4R5, -(alquilo C1-4)NR4COR5, -(alquilo C1-4)NR4COOR5, X es una union o (CH2)aW(CH2)b, (CH2)aW(CH2)bY(CH2)c o- [(CH2)aW(CH2)b)m-(Z)e-[(CH2)cY(CH2)d]n en la cual a, b, c y d son independientemente 0, 1, 2 o 3, e es 0, 1 o 2 y n y m son independientemente 0 o 1 y W es -CO-,-O-, -SO2-,-CH2-, -CHOH-, -NR6-, NR7CONR8 o NR7SO2NR8 e Y es -CO-, -O-, -SO2-, -CH2-, -CHOH- o -NR6, NR7CONR8 o NR7SO2NR8 y Z se selecciona entre el grupo que consiste en cicloalquilo, heterocicloalquilo, arilo y heteroarilo y cuando e es 2, entonces cada una de las partes Z se seleccionan independientemente entre sí; R4, R5 y R6 son independientemente hidrogeno, alquilo C1-4 y donde R4 y R5 juntos pueden formar un anillo compuesto por entre 5 y 7 miembros, R7 y R8 son independientemente hidrogeno, alquilo C1-4 y donde R7 y R8 juntos pueden formar un anillo compuesto por entre 5 y 7 miembros.
ARP100100400A 2009-02-13 2010-02-12 Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa. AR075411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13

Publications (1)

Publication Number Publication Date
AR075411A1 true AR075411A1 (es) 2011-03-30

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100400A AR075411A1 (es) 2009-02-13 2010-02-12 Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa.

Country Status (24)

Country Link
US (1) US20120041195A1 (es)
EP (1) EP2396324A1 (es)
JP (1) JP2012517971A (es)
KR (1) KR20110116160A (es)
CN (1) CN102317288A (es)
AR (1) AR075411A1 (es)
BR (1) BRPI1008850A2 (es)
CA (1) CA2751517A1 (es)
CL (1) CL2011001947A1 (es)
CO (1) CO6420343A2 (es)
CR (1) CR20110386A (es)
DO (1) DOP2011000248A (es)
EA (1) EA201101188A1 (es)
EC (1) ECSP11011250A (es)
HN (1) HN2011002095A (es)
IL (1) IL214426A0 (es)
MX (1) MX2011008549A (es)
NI (1) NI201100151A (es)
NZ (1) NZ594508A (es)
PE (1) PE20120110A1 (es)
SG (1) SG173610A1 (es)
TN (1) TN2011000379A1 (es)
WO (1) WO2010092041A1 (es)
ZA (1) ZA201105896B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201204723A (en) * 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
WO2012143329A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
PE20150354A1 (es) 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
PE20160156A1 (es) 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
KR20220104786A (ko) * 2019-11-22 2022-07-26 메드샤인 디스커버리 아이엔씨. Dna-pk 억제제로서의 피리미도피롤 스피로 화합물 및 이의 유도체

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
JP2003514901A (ja) 1999-11-22 2003-04-22 ワーナー−ランバート・カンパニー キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用
KR101075812B1 (ko) * 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서의 트리아졸로피리다진
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
MX2007002208A (es) 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2600531A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
AU2006254825A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
WO2008051757A1 (en) * 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JP2010514693A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2727036C (en) * 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
JP5595389B2 (ja) * 2008-06-20 2014-09-24 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JP2011530483A (ja) * 2008-08-12 2011-12-22 武田薬品工業株式会社 アミド化合物
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
EA201101188A1 (ru) 2012-04-30
WO2010092041A1 (en) 2010-08-19
CR20110386A (es) 2011-12-02
PE20120110A1 (es) 2012-02-20
TN2011000379A1 (en) 2013-03-27
MX2011008549A (es) 2011-12-06
IL214426A0 (en) 2011-09-27
US20120041195A1 (en) 2012-02-16
SG173610A1 (en) 2011-09-29
CN102317288A (zh) 2012-01-11
NI201100151A (es) 2012-10-03
DOP2011000248A (es) 2011-10-31
NZ594508A (en) 2013-12-20
EP2396324A1 (en) 2011-12-21
ECSP11011250A (es) 2011-10-31
KR20110116160A (ko) 2011-10-25
BRPI1008850A2 (pt) 2016-03-15
CA2751517A1 (en) 2010-08-19
CO6420343A2 (es) 2012-04-16
ZA201105896B (en) 2012-03-28
CL2011001947A1 (es) 2012-03-16
JP2012517971A (ja) 2012-08-09
HN2011002095A (es) 2014-01-06

Similar Documents

Publication Publication Date Title
AR075411A1 (es) Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa.
AU2019301944B2 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
KR102394917B1 (ko) 톨 유사 수용체 조정제 화합물
BR112020022201A2 (pt) análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor
ES2686097T3 (es) Compuestos pirazolopirimidina
HRP20210871T1 (hr) Piridopirimdinonski inhibitori cdk2/4/6
AU2020222346B2 (en) Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2020508310A (ja) インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
RU2013154416A (ru) Новые соединения и композиции для ингибирования nampt
UA124090C2 (uk) Інгібітори тирозинкінази
PE20161251A1 (es) Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4
PE20170198A1 (es) Dinucleotidos ciclicos como moduladores de sting
WO2020012337A1 (en) 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
AR078841A1 (es) Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10
WO2018102452A3 (en) Using substituted pyrazole compounds for treatment of hyperproliferative diseases
CN105407723A (zh) 高效的抗赘生剂和抗增生剂
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
AR087471A1 (es) Metodos de tratamiento de enfermedades degenerativas de la retina
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
MX2017009841A (es) 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia.
PE20130640A1 (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
RU2017106489A (ru) 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2
JP2021521262A (ja) 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
TW202237601A (zh) 介白素-1受體相關激酶(irak)降解物及其用途

Legal Events

Date Code Title Description
FA Abandonment or withdrawal